Perrigo Company (PRGO) Piper Sandler Growth Frontiers Conference summary
Event summary combining transcript, slides, and related documents.
Piper Sandler Growth Frontiers Conference summary
21 Jan, 2026Business Overview and Strategy
Operates in the $400B global self-care market, delivering $30B in annual healthcare savings in the US and EU.
Two-thirds of US households purchased products in 2023, reflecting strong market penetration.
Portfolio is 40% branded (higher margin, growth driver) and 60% store brand (largest US provider).
Focused on consumer-led innovation, expanding store brand business, and brand building.
Well-diversified across global self-care categories, reducing seasonality impacts.
Talent and Organizational Development
Strengthened executive and senior leadership with hires from top consumer organizations, bringing over 200 years of combined experience.
Enhanced consumer focus and healthcare expertise.
Building a winning culture and clear growth strategy.
Financial Priorities and Cost Initiatives
Near-term focus on stabilizing infant formula, targeting $140M annual adjusted operating income recovery by 2025/26.
Project Energize aims for $100M–$110M in cost savings by end of 2026.
Expanding $2.5B US store brand business and optimizing cost structure under One Perrigo model.
Prioritizing free cash flow and deleveraging balance sheet as investment costs wind down.
Ongoing integration of recent acquisitions and cost-reduction efforts to drive growth and efficiency.
Latest events from Perrigo Company
- Proxy covers director elections, compensation, auditor, LTIP, and ESG progress.PRGO
Proxy filing20 Mar 2026 - Key votes include director elections, auditor ratification, and executive compensation approval.PRGO
Proxy filing20 Mar 2026 - Gained OTC market share, drove cost savings, and targets growth through innovation and efficiency.PRGO
UBS Global Consumer and Retail Conference11 Mar 2026 - Adjusted EPS up 7% to $2.75; FY2026 outlook cautious amid cost actions and market headwinds.PRGO
Q4 202526 Feb 2026 - Q3 2024 delivered margin expansion, higher adjusted EPS, and infant formula market share gains.PRGO
Q3 20243 Feb 2026 - Adjusted EPS met expectations as margin gains offset sales declines; 2024 EPS guidance reaffirmed.PRGO
Q2 20242 Feb 2026 - Margin expansion and innovation drive growth, with infant formula and Opill as key catalysts.PRGO
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Cost savings, infant formula rebound, and branded growth set to drive EPS above $3 in 2025.PRGO
Oppenheimer’s 24th Annual Consumer Growth & E-Commerce Conference1 Feb 2026 - Three-year plan targets growth, margin expansion, and higher free cash flow via brand and operational focus.PRGO
UBS Global Consumer and Retail Conference26 Dec 2025